Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 Receptor mutations

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Trier, C, Hollensted, M, Schnurr, TM, Lund, MAV, Nielsen, TRH, Rui, G, Andersson, EA, Svendstrup, M, Bille, DS, Gjesing, AP, Fonvig, CE, Frithioff-Bøjsøe, C, Balslev-Harder, M, Quan, S, Gamborg, M, Pedersen, O, Ängquist, L, Holm, J-C & Hansen, T 2021, 'Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 Receptor mutations', International journal of obesity (2005), bind 45, nr. 1, s. 66-76. https://doi.org/10.1038/s41366-020-00673-6

APA

Trier, C., Hollensted, M., Schnurr, T. M., Lund, M. A. V., Nielsen, T. R. H., Rui, G., Andersson, E. A., Svendstrup, M., Bille, D. S., Gjesing, A. P., Fonvig, C. E., Frithioff-Bøjsøe, C., Balslev-Harder, M., Quan, S., Gamborg, M., Pedersen, O., Ängquist, L., Holm, J-C., & Hansen, T. (2021). Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 Receptor mutations. International journal of obesity (2005), 45(1), 66-76. https://doi.org/10.1038/s41366-020-00673-6

CBE

Trier C, Hollensted M, Schnurr TM, Lund MAV, Nielsen TRH, Rui G, Andersson EA, Svendstrup M, Bille DS, Gjesing AP, Fonvig CE, Frithioff-Bøjsøe C, Balslev-Harder M, Quan S, Gamborg M, Pedersen O, Ängquist L, Holm J-C, Hansen T. 2021. Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 Receptor mutations. International journal of obesity (2005). 45(1):66-76. https://doi.org/10.1038/s41366-020-00673-6

MLA

Vancouver

Author

Trier, Cæcilie ; Hollensted, Mette ; Schnurr, Theresia M ; Lund, Morten Asp Vonsild ; Nielsen, Tenna Ruest Haarmark ; Rui, Gao ; Andersson, Ehm Astrid ; Svendstrup, Mathilde ; Bille, Dorthe Sadowa ; Gjesing, Anette P ; Fonvig, Cilius Esmann ; Frithioff-Bøjsøe, Christine ; Balslev-Harder, Marie ; Quan, Shi ; Gamborg, Michael ; Pedersen, Oluf ; Ängquist, Lars ; Holm, Jens-Christian ; Hansen, Torben. / Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 Receptor mutations. I: International journal of obesity (2005). 2021 ; Bind 45, Nr. 1. s. 66-76.

Bibtex

@article{c45ddfab372f41b19ebae0b1f4386a2a,
title = "Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 Receptor mutations",
abstract = "OBJECTIVES: To determine the prevalence of Melanocortin-4 Receptor (MC4R) mutations in a cohort of children and adolescents with overweight or obesity and to determine whether treatment responses differed between carriers and noncarriers.METHODS: Using target region capture sequencing, an MC4R mutation screen was performed in 1261 Danish children and adolescents enrolled at a tertiary multidisciplinary childhood obesity treatment center. Measurements of anthropometrics, blood pressure, fasting blood biochemistry including lipid and hormone levels, and dual-energy X-ray absorptiometry were performed at baseline and throughout treatment.RESULTS: Of 1209 children and adolescents that met all criteria to be included in the described analyses, 30 (2.5%) carried damaging or unresolved MC4R mutations. At baseline, mutation carriers exhibited higher concentrations of plasma thyroid-stimulating hormone (p = 0.003), and lower concentrations of plasma thyroxine (p = 0.010) compared to noncarriers. After a median of 1 year of treatment (range 0.5-4.0 years), body mass index (BMI) standard deviation score (SDS) was reduced in noncarriers but not in carriers, and this difference in treatment response was statistically significant (p = 0.005). Furthermore, HDL cholesterol was reduced in carriers, a response significantly different from that of noncarriers (p = 0.017).CONCLUSION: Among Danish children and adolescents with overweight or obesity entering a tertiary lifestyle intervention, 2.5% carried damaging or unresolved MC4R mutations. In contrast to noncarriers, carriers of damaging or unresolved MC4R mutations failed to reduce their BMI SDS during obesity treatment, indicating a need for personalized treatment based on the MC4R genotype.",
author = "C{\ae}cilie Trier and Mette Hollensted and Schnurr, {Theresia M} and Lund, {Morten Asp Vonsild} and Nielsen, {Tenna Ruest Haarmark} and Gao Rui and Andersson, {Ehm Astrid} and Mathilde Svendstrup and Bille, {Dorthe Sadowa} and Gjesing, {Anette P} and Fonvig, {Cilius Esmann} and Christine Frithioff-B{\o}js{\o}e and Marie Balslev-Harder and Shi Quan and Michael Gamborg and Oluf Pedersen and Lars {\"A}ngquist and Jens-Christian Holm and Torben Hansen",
year = "2021",
month = jan,
doi = "10.1038/s41366-020-00673-6",
language = "English",
volume = "45",
pages = "66--76",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 Receptor mutations

AU - Trier, Cæcilie

AU - Hollensted, Mette

AU - Schnurr, Theresia M

AU - Lund, Morten Asp Vonsild

AU - Nielsen, Tenna Ruest Haarmark

AU - Rui, Gao

AU - Andersson, Ehm Astrid

AU - Svendstrup, Mathilde

AU - Bille, Dorthe Sadowa

AU - Gjesing, Anette P

AU - Fonvig, Cilius Esmann

AU - Frithioff-Bøjsøe, Christine

AU - Balslev-Harder, Marie

AU - Quan, Shi

AU - Gamborg, Michael

AU - Pedersen, Oluf

AU - Ängquist, Lars

AU - Holm, Jens-Christian

AU - Hansen, Torben

PY - 2021/1

Y1 - 2021/1

N2 - OBJECTIVES: To determine the prevalence of Melanocortin-4 Receptor (MC4R) mutations in a cohort of children and adolescents with overweight or obesity and to determine whether treatment responses differed between carriers and noncarriers.METHODS: Using target region capture sequencing, an MC4R mutation screen was performed in 1261 Danish children and adolescents enrolled at a tertiary multidisciplinary childhood obesity treatment center. Measurements of anthropometrics, blood pressure, fasting blood biochemistry including lipid and hormone levels, and dual-energy X-ray absorptiometry were performed at baseline and throughout treatment.RESULTS: Of 1209 children and adolescents that met all criteria to be included in the described analyses, 30 (2.5%) carried damaging or unresolved MC4R mutations. At baseline, mutation carriers exhibited higher concentrations of plasma thyroid-stimulating hormone (p = 0.003), and lower concentrations of plasma thyroxine (p = 0.010) compared to noncarriers. After a median of 1 year of treatment (range 0.5-4.0 years), body mass index (BMI) standard deviation score (SDS) was reduced in noncarriers but not in carriers, and this difference in treatment response was statistically significant (p = 0.005). Furthermore, HDL cholesterol was reduced in carriers, a response significantly different from that of noncarriers (p = 0.017).CONCLUSION: Among Danish children and adolescents with overweight or obesity entering a tertiary lifestyle intervention, 2.5% carried damaging or unresolved MC4R mutations. In contrast to noncarriers, carriers of damaging or unresolved MC4R mutations failed to reduce their BMI SDS during obesity treatment, indicating a need for personalized treatment based on the MC4R genotype.

AB - OBJECTIVES: To determine the prevalence of Melanocortin-4 Receptor (MC4R) mutations in a cohort of children and adolescents with overweight or obesity and to determine whether treatment responses differed between carriers and noncarriers.METHODS: Using target region capture sequencing, an MC4R mutation screen was performed in 1261 Danish children and adolescents enrolled at a tertiary multidisciplinary childhood obesity treatment center. Measurements of anthropometrics, blood pressure, fasting blood biochemistry including lipid and hormone levels, and dual-energy X-ray absorptiometry were performed at baseline and throughout treatment.RESULTS: Of 1209 children and adolescents that met all criteria to be included in the described analyses, 30 (2.5%) carried damaging or unresolved MC4R mutations. At baseline, mutation carriers exhibited higher concentrations of plasma thyroid-stimulating hormone (p = 0.003), and lower concentrations of plasma thyroxine (p = 0.010) compared to noncarriers. After a median of 1 year of treatment (range 0.5-4.0 years), body mass index (BMI) standard deviation score (SDS) was reduced in noncarriers but not in carriers, and this difference in treatment response was statistically significant (p = 0.005). Furthermore, HDL cholesterol was reduced in carriers, a response significantly different from that of noncarriers (p = 0.017).CONCLUSION: Among Danish children and adolescents with overweight or obesity entering a tertiary lifestyle intervention, 2.5% carried damaging or unresolved MC4R mutations. In contrast to noncarriers, carriers of damaging or unresolved MC4R mutations failed to reduce their BMI SDS during obesity treatment, indicating a need for personalized treatment based on the MC4R genotype.

UR - http://www.scopus.com/inward/record.url?scp=85090940705&partnerID=8YFLogxK

U2 - 10.1038/s41366-020-00673-6

DO - 10.1038/s41366-020-00673-6

M3 - Journal article

C2 - 32921795

VL - 45

SP - 66

EP - 76

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 1

ER -

ID: 61714133